Skip to main content

Table 3 Cost-effectiveness results of base case analysis (SOT analysis of ROCKET AF trial data)

From: Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece

 

Rivaroxaban

VKA

Costs

Total costs (€)

7,868

8,107

Drug acquisition cost (€)

4,156

126

Drug monitoring costs (€)

52

3,981

Event treatment costs (€)

3,659

4,000

Health outcomes

QALYs

6.50

6.28

LYs

8.55

8.48

Strokes

0.22

0.23

Bleeds

1.10

1.06

Incremental analysis

ICER per QALY gained (€)

NA

Riv. Dom

ICER per LY gained (€)

NA

Riv. Dom

  1. It is assumed that patients receiving either rivaroxaban or acenocoumarol are switched to aspirin monotherapy.
  2. SOT safety on treatment, QALYs quality-adjusted-life-years, LYs Life-Years, NA not applicable, Riv. Dom Rivaroxaban is dominant, ICER incremental cost effectiveness ratio, VKA vitamin-K-antagonist.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us